Letter to the Editor
Keyword(s):
Dr Zucker's letter describes concern about the American Academy of Pediatrics (AAP) Committee on Infectious Diseases statement on the use of ribavirin for the treatment of respiratory syncytial virus (RSV) infections (Pediatrics 1993;92:501-504). The Committee developed its recommendations on the basis of the available placebo-controlled prospective double-blind studies. Although these studies contained relatively small numbers of patients, they were controlled and prospective, and all showed a favorable response. The variable course of RSV illnesses and the relatively low mortality rates make clinically meaningful end-points difficult to define and quantitate.
2018 ◽
Vol 35
(14)
◽
pp. 1433-1442
◽
2015 ◽
Vol 4
(4)
◽
pp. 503-511
◽
2019 ◽
Vol 37
(02)
◽
pp. 174-183
◽